John C. Byrd, MD

Bhatnagar, Bhavana; Kohlschmidt, Jessica; Mrózek, Krzysztof; Zhao, Qiuhong; Fisher, James L; Nicolet, Deedra; Walker, Christopher J; Mims, Alice S; Oakes, Christopher; Giacopelli, Brian; Orwick, Shelley; Boateng, Isaiah; Blachly, James S; Maharry, Sophia E; Carroll, Andrew J; Powell, Bayard L; Kolitz, Jonathan E; Stone, Richard M; Byrd, John C; Paskett, Electra D; de la Chapelle, Albert; Garzon, Ramiro; Eisfeld, Ann-Kathrin 2021. Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia. Cancer discovery, 11 3, 626-637

Eisenmann, Eric D; Fu, Qiang; Muhowski, Elizabeth M; Jin, Yan; Uddin, Muhammad Erfan; Garrison, Dominique A; Weber, Robert H; Woyach, Jennifer; Byrd, John C; Sparreboom, Alex; Baker, Sharyn D 2021. Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition. Cancer research communications, 1 2, 79-89

Kittai, Adam S; Miller, Cecelia; Goldstein, Daniel; Huang, Ying; Abruzzo, Lynne V; Beckwith, Kyle; Bhat, Seema A; Bond, David A; Grever, Michael R; Heerema, Nyla A; Rogers, Kerry A; Ruppert, Amy S; Byrd, John C; Woyach, Jennifer A 2021. The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib. Blood, 138 23, 2372-2382

Larkin, Karilyn T M; Byrd, John C 2021. Whole-genome sequencing for myeloid disease: one assay to stratify them all? Nature reviews. Clinical oncology, ,

O'Brien, Susan M; Brown, Jennifer R; Byrd, John C; Furman, Richard R; Ghia, Paolo; Sharman, Jeff P; Wierda, William G 2021. Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice. Frontiers in oncology, 11 , 720704

Walker, Alison R; Byrd, John C; Blachly, James S; Bhatnagar, Bhavana; Mims, Alice S; Orwick, Shelley; Lin, Tara L; Crosswell, Howland E; Zhang, Danjie; Minden, Mark D; Munugalavadla, Veerendra; Long, Lauren; Liu, Jinfeng; Pan, Yang; Oellerich, Thomas; Serve, Hubert; Rao, Arati V; Blum, William G 2020. Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression. Clinical cancer research : an official journal of the American Association for Cancer Research, 26 22, 5852-5859

Greene, J T; Mani, Rajeswaran; Ramaswamy, Rahul; Frissora, Frank; Yano, Max; Zapolnik, Kevan; Harrington, Bonnie; Wasmuth, Ronni; Tran, Minh; Mo, Xiaokui; McKenna, Mary; Rangnekar, Vivek M; Byrd, John C; Bondada, Subbarao; Muthusamy, Natarajan 2019. Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling. Blood advances, 3 8, 1255-1266

Rosko, Ashley E; Huang, Ying; Benson, Don M; Efebera, Yvonne A; Hofmeister, Craig; Jaglowski, Samantha; Devine, Steven; Bhatt, Geetika; Wildes, Tanya M; Dyko, Alanna; Jones, Desirée; Naughton, Michelle J; Byrd, John C; Burd, Christin E 2019. Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant. Journal of geriatric oncology, 10 3, 479-485

Reiff, Sean D; Mantel, Rose; Smith, Lisa L; Greene, J T; Muhowski, Elizabeth M; Fabian, Catherine A; Goettl, Virginia M; Tran, Minh; Harrington, Bonnie K; Rogers, Kerry A; Awan, Farrukh T; Maddocks, Kami; Andritsos, Leslie; Lehman, Amy M; Sampath, Deepa; Lapalombella, Rosa; Eathiraj, Sudharshan; Abbadessa, Giovanni; Schwartz, Brian; Johnson, Amy J; Byrd, John C; Woyach, Jennifer A 2018. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. Cancer discovery, 8 10, 1300-1315

Woyach, Jennifer A; Ruppert, Amy S; Heerema, Nyla A; Zhao, Weiqiang; Booth, Allison M; Ding, Wei; Bartlett, Nancy L; Brander, Danielle M; Barr, Paul M; Rogers, Kerry A; Parikh, Sameer A; Coutre, Steven; Hurria, Arti; Brown, Jennifer R; Lozanski, Gerard; Blachly, James S; Ozer, Hatice G; Major-Elechi, Brittny; Fruth, Briant; Nattam, Sreenivasa; Larson, Richard A; Erba, Harry; Litzow, Mark; Owen, Carolyn; Kuzma, Charles; Abramson, Jeremy S; Little, Richard F; Smith, Scott E; Stone, Richard M; Mandrekar, Sumithra J; Byrd, John C 2018. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. The New England journal of medicine, 379 26, 2517-2528

Korman, Abraham M; Hastings, Justin G; Byrd, John C; Kaffenberger, Benjamin H 2017. Sweet-Like Eruption Associated With Obinutuzumab Therapy for Chronic Lymphocytic Leukemia. JAMA dermatology, 153 1, 108-110

Flinn, Ian W; Ruppert, Amy S; Harwin, William; Waterhouse, David; Papish, Steven; Jones, Jeffrey A; Hainsworth, John; Byrd, John C 2016. A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia. American journal of hematology, 91 10, 1020-5

Harrington, Bonnie K; Gardner, Heather L; Izumi, Raquel; Hamdy, Ahmed; Rothbaum, Wayne; Coombes, Kevin R; Covey, Todd; Kaptein, Allard; Gulrajani, Michael; Van Lith, Bart; Krejsa, Cecile; Coss, Christopher C; Russell, Duncan S; Zhang, Xiaoli; Urie, Bridget K; London, Cheryl A; Byrd, John C; Johnson, Amy J; Kisseberth, William C 2016. Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma. PloS one, 11 7, e0159607

Horwitz, Steven M; Zelenetz, Andrew D; Gordon, Leo I; Wierda, William G; Abramson, Jeremy S; Advani, Ranjana H; Andreadis, C Babis; Bartlett, Nancy; Byrd, John C; Fayad, Luis E; Fisher, Richard I; Glenn, Martha J; Habermann, Thomas M; Lee Harris, Nancy; Hernandez-Ilizaliturri, Francisco; Hoppe, Richard T; Kaminski, Mark S; Kelsey, Christopher R; Kim, Youn H; Krivacic, Susan; LaCasce, Ann S; Lunning, Matthew; Nademanee, Auayporn; Press, Oliver; Rabinovitch, Rachel; Reddy, Nishitha; Reid, Erin; Roberts, Kenneth; Saad, Ayman A; Sokol, Lubomir; Swinnen, Lode J; Vose, Julie M; Yahalom, Joachim; Zafar, Nadeem; Dwyer, Mary; Sundar, Hema; Porcu, Pierluigi 2016. NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. Journal of the National Comprehensive Cancer Network : JNCCN, 14 9, 1067-79

Browning, Rebekah L; Mo, Xiaokui; Muthusamy, Natarajan; Byrd, John C 2015. CpG oligodeoxynucleotide CpG-685 upregulates functional interleukin-21 receptor on chronic lymphocytic leukemia B cells through an NF-κB mediated pathway. Oncotarget, 6 18, 15931-9

Christian, Beth A; Poi, Ming; Jones, Jeffrey A; Porcu, Pierluigi; Maddocks, Kami; Flynn, Joseph M; Benson, Don M; Phelps, Mitch A; Wei, Lai; Byrd, John C; Wegener, William A; Goldenberg, David M; Baiocchi, Robert A; Blum, Kristie A 2015. The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. British journal of haematology, 169 5, 701-10

Awan, Farrukh T; Hillmen, Peter; Hellmann, Andrzej; Robak, Tadeusz; Hughes, Steven G; Trone, Denise; Shannon, Megan; Flinn, Ian W; Byrd, John C 2014. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. British journal of haematology, 167 4, 466-77

Ji, Jia; Mould, Diane R; Blum, Kristie A; Ruppert, Amy S; Poi, Ming; Zhao, Yuan; Johnson, Amy J; Byrd, John C; Grever, Michael R; Phelps, Mitch A 2013. A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol. Clinical cancer research : an official journal of the American Association for Cancer Research, 19 5, 1269-80

Rafiq, Sarwish; Butchar, Jonathan P; Cheney, Carolyn; Mo, Xiaokui; Trotta, Rossana; Caligiuri, Michael; Jarjoura, David; Tridandapani, Susheela; Muthusamy, Natarajan; Byrd, John C 2013. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. Journal of immunology (Baltimore, Md. : 1950), 190 6, 2702-11

Zelenetz, Andrew D; Wierda, William G; Abramson, Jeremy S; Advani, Ranjana H; Andreadis, C Babis; Bartlett, Nancy; Bellam, Naresh; Byrd, John C; Czuczman, Myron S; Fayad, Luis E; Glenn, Martha J; Gockerman, Jon P; Gordon, Leo I; Harris, Nancy Lee; Hoppe, Richard T; Horwitz, Steven M; Kelsey, Christopher R; Kim, Youn H; Krivacic, Susan; LaCasce, Ann S; Nademanee, Auayporn; Porcu, Pierluigi; Press, Oliver; Pro, Barbara; Reddy, Nishitha; Sokol, Lubomir; Swinnen, Lode; Tsien, Christina; Vose, Julie M; Yahalom, Joachim; Zafar, Nadeem; Dwyer, Mary A; Naganuma, Maoko 2013. Non-Hodgkin's lymphomas, version 1.2013. Journal of the National Comprehensive Cancer Network : JNCCN, 11 3, 257-72; quiz 273

Awan, Farrukh T; Lapalombella, Rosa; Trotta, Rossana; Butchar, Jonathan P; Yu, Bo; Benson, Don M; Roda, Julie M; Cheney, Carolyn; Mo, Xiaokui; Lehman, Amy; Jones, Jeffrey; Flynn, Joseph; Jarjoura, David; Desjarlais, John R; Tridandapani, Susheela; Caligiuri, Michael A; Muthusamy, Natarajan; Byrd, John C 2010. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood, 115 6, 1204-13

Ni, Wenjun; Ji, Jia; Dai, Zunyan; Papp, Audrey; Johnson, Amy J; Ahn, Sunjoo; Farley, Katherine L; Lin, Thomas S; Dalton, James T; Li, Xiaobai; Jarjoura, David; Byrd, John C; Sadee, Wolfgang; Grever, Michael R; Phelps, Mitch A 2010. Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PloS one, 5 11, e13792

Sanchez-Aguilera, A; Rattmann, I; Drew, D Z; Müller, L U W; Summey, V; Lucas, D M; Byrd, J C; Croce, C M; Gu, Y; Cancelas, J A; Johnston, P; Moritz, T; Williams, D A 2010. Involvement of RhoH GTPase in the development of B-cell chronic lymphocytic leukemia. Leukemia, 24 1, 97-104

Garzon, Ramiro; Liu, Shujun; Fabbri, Muller; Liu, Zhongfa; Heaphy, Catherine E A; Callegari, Elisa; Schwind, Sebastian; Pang, Jiuxia; Yu, Jianhua; Muthusamy, Natarajan; Havelange, Violaine; Volinia, Stefano; Blum, William; Rush, Laura J; Perrotti, Danilo; Andreeff, Michael; Bloomfield, Clara D; Byrd, John C; Chan, Kenneth; Wu, Lai-Chu; Croce, Carlo M; Marcucci, Guido 2009. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood, 113 25, 6411-8

Liu, Qing; Zhao, Xiaobin; Frissora, Frank; Ma, Yihui; Santhanam, Ramasamy; Jarjoura, David; Lehman, Amy; Perrotti, Danilo; Chen, Ching-Shih; Dalton, James T; Muthusamy, Natarajan; Byrd, John C 2008. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood, 111 1, 275-84

Treon, Steven P.; Agus, David B.; Link, Brian; Rodrigues, Gilberto; Molina, Arturo; Lacy, Martha Q.; Fisher, David C.; Emmanouilides, Christos; Richards, Arthur I.; Clark, Bruce; Lucas, Marjorie S.; Schlossman, Robert; Schenkein, David; Lin, Boris; Kimby, Eva; Anderson, K. C.; Byrd, John C. 2001. CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. Journal of immunotherapy : official journal of the Society for Biological Therapy, 24 3, 272-279